The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine and integrin receptors 1 . Its requirement for complete RAS-MAPK activation and its role as a negative regulator of JAK-STAT signaling have established SHP2 as an essential player in oncogenic signaling pathways [1] [2] [3] [4] [5] [6] [7] . Recently, a novel potent allosteric SHP2 inhibitor was presented as a viable therapeutic option for receptor tyrosine kinase-driven cancers, but was shown to be ineffective in KRAS-mutant tumor cell lines in vitro 8 . Here, we report a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors. Genetic deletion of Ptpn11 profoundly inhibited tumor development in mutant KRAS-driven murine models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer. We provide evidence for a critical dependence of mutant KRAS on SHP2 during carcinogenesis. Deletion or inhibition of SHP2 in established tumors delayed tumor progression but was not sufficient to achieve tumor regression. However, SHP2 was necessary for resistance mechanisms upon blockade of MEK. Synergy was observed when both SHP2 and MEK were targeted, resulting in sustained tumor growth control in murine and human patient-derived organoids and xenograft models of pancreatic ductal adenocarcinoma and non-small-cell lung cancer. Our data indicate the clinical utility of dual SHP2/MEK inhibition as a targeted therapy approach for KRAS-mutant cancers.
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RAS genes constitute the most frequently mutated oncogene family in human cancers 9 . Although KRAS mutations are virtually universal in pancreatic ductal adenocarcinoma (PDAC), they occur in up to 30% of non-small-cell lung cancer (NSCLC) 9, 10 . Recently, genome-wide association analysis and functional characterization identified the long intergenic noncoding RNA LINC00673 as a potential tumor suppressor that acts through regulation of pre-mRNA-processing factor 19 (PRPF19)-mediated ubiquitination and degradation of SHP2 (encoded by PTPN11) in PDAC. The germline G > A variation at rs11655237 impairs this effect of LINC00673 and confers susceptibility to tumorigenesis 11 , implying a proto-oncogenic role for SHP2. In addition, SHP2 promotes RAS-RAF-MAP-kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling in NSCLC with epidermal growth factor receptor (EGFR)-activating mutations 12, 13 , but evidence for its relevance in KRAS-mutant NSCLC is lacking.
Oncogenomic database analysis together with protein expression profiling in several human PDAC and NSCLC tissues and cell lines revealed the epithelial presence of SHP2 ( Supplementary Fig. 1a-e) . As a sign of recruitment and activation, its Y542 phosphorylation [14] [15] [16] was detected in a heterogeneous pattern in the majority of samples analyzed ( Supplementary Fig. 1b-d ). Transcriptional levels of PTPN11 had no clear association with overall survival in The Cancer Genome Atlas (TCGA) RNA-seq PDAC and NSCLC (KRAS-mutant subgroup) data sets ( Supplementary Fig. 1f,g ). These results suggest that SHP2 activation, rather than expression levels, determines its action in PDAC and NSCLC.
To genetically dissect the contribution of SHP2 in PDAC and NSCLC tumorigenesis, we utilized oncogenic KRAS-driven murine cancer models, which allow for tissue-specific expression of the G12D mutation in KRAS (KRAS G12D ) and the initiation of tumors in the pancreas or lung 17, 18 . In both PDAC and NSCLC models, SHP2 expression was observed during the entire process of tumor development ( Supplementary Fig. 2a-e) . Pancreas-specific biallelic deletion of Ptpn11 in KRAS G12D mice (termed: Kras), but not monoallelic deletion (data not shown), led to profound inhibition of pancreatic intraepithelial neoplasia (PanIN) development (Fig. 1a,b and Supplementary Fig. 3a ), pancreatic enlargement ( Supplementary  Fig. 3b ) and desmoplasia ( Fig. 1a and Supplementary Fig. 3c ). PDAC formation was almost completely blocked, and survival was dramatically prolonged when Ptpn11 was deleted ( Fig. 1c and Supplementary Fig. 3d ). Likewise, inflammation-triggered acceleration of pancreatic carcinogenesis by cerulein was inhibited in the absence of SHP2 ( Supplementary Fig. 3e-h ). In an ex vivo acinarto-ductal metaplasia assay
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PDAC mouse models with loss of Ink4a/Arf 20 or monoallelic/biallelic deletion of Trp53 (ref.
21
). Strikingly, even in these backgrounds, Ptpn11 deficiency potently blocked PanIN progression and PDAC development, translating into significant and extended tumor-free survival ( -driven model of NSCLC. The pulmonary 'atypical adenomatous hyperplasia-adenoma-adenocarcinoma' progression sequence was significantly delayed in the absence of Ptpn11 ( Supplementary Fig. 5a -c,f). Even in the more-rapid Kras;Trp53 −/− context, loss of Ptpn11 resulted in a substantial deceleration of NSCLC disease dynamics and reduced tumor burden, which translated into considerably prolonged survival ( Fig. 1f and Supplementary Fig. 5d ,e,g,h). Of note, unlike in the PDAC models, a substantial fraction of tumors that emerged in the NSCLC models demonstrated escape from Ptpn11 deletion ( Supplementary Fig. 5i ).
Taken together, these in vivo data indicate a central and indispensable role for SHP2 in carcinogenesis of oncogenic KRAS-driven epithelial tumors of the pancreas and lung.
Formation of preneoplastic lesions and progression to carcinoma in these KRAS G12D -driven models correlates with enhancement of RAF-MEK-ERK signaling 22, 23 . However, phosphorylation of ERK in early-transforming Kras pancreata or lungs was greatly diminished in Kras;Ptpn11 −/− mice ( Fig. 2a and Supplementary  Figs. 5j,k and 6a ). In addition, the direct and indirect oncogenic RAS-effector phosphatidylinositol-3-OH kinase (PI3K)-AKT and signal transducer and activator of transcription 3 (STAT3) pathways were activated in transforming Kras, but not in Kras;Ptpn11 −/− pancreata (Fig. 2a) ;Ptpn11 −/− mice (n = 19, median: undefined). Ticks indicate censored mice that were euthanized due to paraparesis, without histological evidence of more than rare lowgrade PanIN in the pancreas (see Supplementary Fig. 4d ;Ptpn11 −/− (n = 16) animals in the whole survival analysis cohorts with similar results. The mice shown here were chosen for demonstrative reasons given their equal survival time. Scale bars, 1,000 µ m. Insets: magnification × 10.
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on pancreatic tissue samples from 9-week-old mice. Gene set enrichment analysis (GSEA) revealed a remarkably skewed pattern of significantly enriched gene sets in favor of Kras compared to Kras;Ptpn11 −/− samples ( Fig. 2c and Supplementary Fig. 6b ,c). Enriched gene sets in Kras tissue included established oncogenic facets, such as increased transcriptional activity, transdifferentiation, cell stress and altered metabolism, as well as inflammation, desmoplasia and (re-)activation of embryonic signaling cascades ( Supplementary Fig. 6b-f ). More importantly, a clear loss of a KRAS signaling signature was evident in Kras;Ptpn11 −/− samples (Fig. 2d) . Consequently, and consistent with the findings in Fig. 2a , signatures related to pathways that are known to be directly or indirectly linked to oncogenic KRAS, such as MEK, AKT and interleukin-6 (IL-6)-Janus kinase (JAK)-STAT3 signaling were lost with Ptpn11 deletion (Supplementary Fig. 6h ). In addition, Kras samples demonstrated enrichment of signatures of multiple growth factors, 
Pik3ca; Ptpn11
+/-
-/-
Map2k1; Ptpn11
+/- , respectively). Numerical values indicate the ratio of densitometrically quantified signals from pulldown over input samples. Ratios are illustrated by the panels on the right. For uncropped images, including molecular weight markers, see Supplementary Fig. 18b. c,d , GSEA of mRNA microarray data from pancreatic tissue samples of 9-week-old Kras and Kras;Ptpn11 −/− mice (n = 3 animals per group); analysis and statistics were performed using GSEA software provided by the Broad Institute, as previously described 42 . Supplementary Fig. 6g ). To further demonstrate the dependency of oncogenic KRAS on SHP2 in pancreatic carcinogenesis, we first bred Ptpn11 mice with MAP2K1 DD or PIK3CA H1047R mice 25, 26 . These crossings revealed that Ptpn11 is redundant in the presence of constitutively active mutant MEK1 or PI3K (Fig. 2e) and, therefore, SHP2 functions upstream, at the level of KRAS. Given the pleiotropic regulatory effects of SHP2 on signaling pathways, and its inhibitory role in the STAT3 pathway in particular 6 , we further utilized a previously published KRAS G12D mouse model lacking the negative-feedback STAT3 regulator SOCS3 specifically in the pancreas (Kras;Socs3 −/− ) 27 . Loss of Ptpn11 in this model did not further aggravate but rescued the aggressive STAT3-dependent phenotype of PDAC development ( Supplementary Fig. 7a-c frt/frt alleles were monitored with magnetic resonance imaging (MRI) for tumor occurrence. Upon tumor detection, deletion of Ptpn11 was achieved by a tamoxifen-inducible Cre-recombinase, which was expressed exclusively in the Flpo-recombined epithelial PDAC compartment (FSF-CreRT). Subsequently, tumor dynamics were evaluated weekly with MRI (Fig. 3a) . These experiments revealed that deletion of Ptpn11 in established murine PDAC epithelia was not sufficient to achieve tumor regression or prolong survival, but led to slower tumor growth and reduced pan-RAS and KRAS G12D activity levels in vivo and in vitro; tumor morphology was unchanged ( Aiming to identify pharmacological vulnerabilities conferred by loss of SHP2, we performed a focused drug screen with PTPN11-knockout cells using PDAC-and NSCLC-relevant chemotherapeutics (gemcitabine, oxaliplatin and paclitaxel) and selected small molecules targeting RAS downstream effector kinases (PI3K and MEK). These experiments revealed that PTPN11-knockout cells were uniquely susceptible to MEK inhibitors ( Fig. 3f and Supplementary Fig. 9a,b ). Intrinsic and acquired resistance to MEK inhibition is a common phenomenon that has been attributed to activation of RTK signaling in KRAS-mutant and BRAF-mutant contexts [29] [30] [31] [32] [33] [34] . Thus, MEK inhibitors have failed to enter into the clinic as a single adjunct to conventional chemotherapy in PDAC and NSCLC 35, 36 . The KRAS-mutant human PDAC cell lines YAPC, PANC-1 and DAN-G are relatively resistant to MEK inhibition, whereas CAPAN-2 is sensitive to MEK inhibition ( Supplementary  Fig. 10a ). After prolonged treatment with selumetinib (a MEK inhibitor), the phosphorylation levels of ERK increased steadily over time, reaching near to the untreated control levels in YAPC, PANC-1 and DAN-G cells, whereas CAPAN-2 cells were incapable of reactivating ERK ( Supplementary Fig. 10b ). In parallel, we observed phosphorylation of multiple RTKs, strong Y542 phosphorylation and increased phosphatase activity of SHP2 upon treatment with selumetinib ( Fig. 3g and Supplementary Fig. 10b-f ), suggesting that SHP2 transmits a RTK-mediated feedback loop, conferring resistance to MEK inhibitors. Indeed, YAPC and PANC-1 PTPN11-knockout cells were incapable of reactivating mitogen-activated protein kinase (MAPK) signaling in the presence of selumetinib ( Fig. 3h and Supplementary Fig. 10g ). Reconstitution of wild-type SHP2 or phosphatase-dead SHP2 C459S in the PTPN11-knockout cells demonstrated the requirement of SHP2 phosphatase activity for restoration of MAPK signaling and proliferative capacity in response to selumetinib ( Supplementary Fig. 11a ,b). As these results provided a strong rationale for a dual SHP2/MEK inhibition, we targeted SHP2 in co-inhibition assays with two different compounds that have been previously characterized in detail: the catalytic-site inhibitor GS493 (ref.
37
) or the recently reported compound SHP099 (refs 8, 38 ), which allosterically stabilizes SHP2 in its closed autoinhibited conformation 38 . Their different modes of action were confirmed in a PTPN11-knockout PANC-1 cell line, reconstituted with the SHP2 E76A mutation, which perturbs autoinhibition and thus renders the allosteric inhibitor ineffective ( Supplementary Fig. 11c ). Both compounds phenocopied the effect seen in PTPN11-knockout cells and demonstrated remarkable synergism with the MEK inhibitors selumetinib and trametinib in multiple murine and human PDAC and NSCLC cell lines. In addition, GS493 and SHP099 showed synergistic potential in combination with PI3K inhibitors, but not with conventional chemotherapeutics (Fig. 3i and Supplementary  Figs . 11d− h and 12a,b). The panels in Supplementary Fig. 13a ,b demonstrate that synergism of combined SHP2/MEK inhibition is not only restricted to the KRAS mutant but is also evident in various KRAS wild-type tumor cell lines.
To test the translational relevance of our findings, we set up three levels of experiments. We first treated endogenous PDACbearing Kras;Trp53 −/− mice with GS493, trametinib or in combination. Similar to the results with human cell line xenotransplants ( Supplementary Fig. 8l ), GS493 alone only modestly inhibited tumor progression. As reported for selumetinib 39 , trametinib, which possesses superior pharmacodynamics compared to other MEK inhibitors 40 , achieved initial pancreatic volume reduction, but eventually, resistant tumors emerged. However, co-treatment with trametinib + GS493 impeded resistance dynamics and achieved sustained tumor growth inhibition ( Fig. 4d and Supplementary  Fig. 16 ). Last, patient-derived KRAS G12D tumor tissue xenografts demonstrated in vivo susceptibility to combined SHP2/MEK inhibition (Fig. 4e,f and Supplementary Fig. 17a− d ). As illustrated with PDAC ID_02, trametinib induced the enhancement of pan-RAS and KRAS G12D activity as well as the PI3K pathway; however, in the dual treatment arm, these effects were constrained, culminating in significantly reduced proliferation, elevated cleaved caspase 3 levels and complete growth inhibition. Of note, SHP2 inhibition did not have detrimental effects on STAT3 phosphorylation. Taken together, these results demonstrate a potent synergistic effect of combined SHP2 and MEK inhibition in KRAS-mutant carcinomas.
Although SHP2 has been considered to be dispensable for mutated oncogenic KRAS function 8 , using mouse and human pancreatic and lung cancer models combined with genetic and pharmacological inhibition approaches, our data indicate that oncogenic KRAS activity depends on SHP2 for its intensification and for downstream signaling during carcinogenesis. In established tumors, loss or inhibition of SHP2 decelerates tumor progression and, more In panel e, the loss of SHP2 was confirmed by immunoblot. Pulldown of RAS-GTP was performed with RAF-RBD agarose beads. Precipitates and input samples were analyzed using the respective antibodies (for an explanation of the labeling, see the legend for Fig. 2b) . Numerical values indicate the ratio of densitometrically quantified signals from pulldown over input samples. β -Actin represents the loading control. One experiment was performed. Full scan images are shown in Supplementary  Fig. 18c . f, Colony formation assays with YAPC and PANC-1 PTPN11 wild-type (WT) versus knockout (KO) cells (two independent PTPN11-knockout cell lines are shown), treated with the MEK inhibitors selumetinib or trametinib at the indicated concentrations. Three independently repeated experiments were performed with similar results. g, Phospho-RTK Array with lysates from YAPC wild-type cells treated with selumetinib for 48 h versus untreated control (ctrl). RTKs with enhanced phosphorylation (antibodies are spotted in duplicate) in response to selumetinib are indicated with colored boxes. One experiment was performed. h, Immunoblot of lysates from YAPC wild-type and PTPN11-knockout clone #1.1 and #2.12 cells treated with selumetinib for the indicated hours. HSP90 served as the loading control. Three independently repeated experiments were performed with similar results. Full scan images are shown in Supplementary Fig. 18d . For the corresponding analysis with PANC-1 cells, see Supplementary Fig. 10g . i, In vitro co-inhibition of MEK (selumetinib) and SHP2 (GS493 or SHP099) in colony formation experiments with YAPC and PANC-1 human pancreatic cancer cell lines. Three independently repeated experiments were performed with similar results. For additional co-inhibition combinations and experiments with DAN-G, see Supplementary Fig. 11d ; for quantification and calculation of combination index scores, see Supplementary Fig. 11e ,f.
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RTK-RAS signaling downstream of almost all RTKs, our findings, together with those from the accompanying manuscript by Mainardi et al. 41 , reveal that SHP2 may hold promise as a therapeutic target not only in RTK-driven tumors but also in KRAS-mutant tumors.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0024-8. Supplementary Fig. 17a . f, Immunoblots and RAF-RBD agarose pulldowns of tissue lysates from PDAC ID_02 tissue xenograft tumors treated for 28 days as indicated. Pulldown of RAS-GTP was achieved using RAF-RBD agarose beads. Precipitates and input samples were analyzed using the respective antibodies (for an explanation of the labeling, see the legend for Fig. 2b ). β -Actin served as the loading control. One experiment was performed. For uncropped images, including molecular weight markers, see Supplementary Fig. 18e . Cl.Casp. 3, cleaved caspase 3; G, GS493; T, trametinib; TG, trametinib + GS493; V, vehicle. Cre-ex1
were born at the expected Mendelian frequency and did not show any signs of impaired health, even with progressing age (data not shown). For mice of the lung tumor cohorts, nomenclature corresponds to those used for PDAC mice; yet, for NSCLC mice, Ptf1a
Cre-ex1 was replaced by inhalation of AdCre. All mice were kept in a mixed genetic background. Genotypes were determined by PCR and gel electrophoresis at weaning and after death. NSG mice were obtained from Jackson Laboratory and bred under a Material Transfer Agreement with Klinikum rechts der Isar, Technische Universität München, Munich, Germany. All animal experiments and care were in accordance with the guidelines of institutional committees and approved by the local authority, Regierung von Oberbayern.
Inflammation-triggered accelerated pancreatic carcinogenesis. Chronic pancreatitis was induced by repetitive supramaximal stimulation with the cholecystokinin analogue cerulein (Sigma-Aldrich). Beginning at 8 weeks of age, Kras and Kras;Ptpn11
−/− mice received 5 daily intraperitoneal high-dose injections of the secretagogue (200 µ g per kg body weight) followed by 2 days of rest for a period of 4 consecutive weeks. Animals were euthanized and analyzed at 13 weeks of age (see schematic in Supplementary Fig. 3e ).
Pancreatic epithelial explants: isolation and in vitro transdifferentiation assay.
Pancreatic epithelial explants from 4-week-old Kras and Kras;Ptpn11
−/− mice were established by slightly modified previously published protocols 19, 48 . In brief, the whole pancreas was collected and treated twice with 1.2 mg ml -1 collagenase from Clostridium histolyticum (Sigma-Aldrich). Following three wash steps with McCoy's 5A medium (Sigma-Aldrich) containing 0.2 mg ml -1 soybean trypsin inhibitor (Sigma-Aldrich) and 0.1% (w/v) BSA (Sigma-Aldrich), digested samples were filtered through a 100-µ m cell strainer, resuspended in recovery medium (DMEM/F12 supplemented with 20% FBS and penicillin-streptomycin (100 U ml -1 , 100 µ g ml -1 ) (all from Life Technologies)) and allowed to recover for 1 h at 37 °C. Subsequently, cells were pelleted and either washed in ice-cold PBS and lysed for immunoblot analyses or resuspended in culture medium, consisting of Waymouth's MB 752/1 (Life Technologies) supplemented with 0.2 mg ml -1 soybean trypsin inhibitor, 50 µ g ml -1 bovine pituitary extract (Life Technologies), insulintransferrin-selenium (10 mg ml ; Life Technologies), 0.1% FBS and penicillin-streptomycin. Rat tail collagen type I (Corning) at a final concentration of 2.5 mg ml -1 was added and the suspension was immediately plated into wells precoated with 2.5 mg ml -1 rat tail collagen type I. After solidification, culture medium was placed on top of the gel. Explants were treated with the indicated final concentrations of the SHP2 phosphatase inhibitor PHPS1 (Sigma-Aldrich) or vehicle control (DMSO) on day 1 and day 3 after plating. For quantification, acinar explants were seeded in triplicates. At day 5, all cell clusters were counted throughout whole wells and reported as a percentage of duct-like spheres and acinar clusters.
AdCre delivery and NSCLC model. Sporadic expression of Cre in mouse lungs was achieved by transnasal inhalation of engineered adenovirus (University of Iowa, Viral Vector Core) as previously described 49 . Following anesthesia with intraperitoneal medetomidine (0.5 mg per kg), midazolam (5 mg per kg) and fentanyl (0.05 mg per kg), a final volume of 60 µ l MEM carrying 5 × 10 7 p.f.u. calcium phosphate co-precipitated AdCre was dispensed dropwise over the left nostril of 6-8-week-old mice until inhaled in its entirety. Analgosedation was antagonized by subcutaneous atipamezole (2.5 mg per kg), flumazenil (0.5 mg per kg) and naloxone (1.2 mg per kg), and mice were monitored under a heat lamp in the biosafety hood until completely recovered.
Dual-recombinase system. Sequential genetic manipulation of the murine pancreas was accomplished through a combined Flpo-FRT and Cre-loxP system as previously reported 28 . Pancreatic tumors were initiated by Pdx-Flpo-mediated recombination of Kras FSF-G12D/+ and Trp53 frt/frt alleles and expressed a tamoxifeninducible Cre-recombinase from the R26 locus (R26
FSF-CAG-CreERT2
). Mice were monitored by MRI, as described below, and received 3 mg tamoxifen (in 150 µ l corn oil; Sigma-Aldrich) per oral gavage on 3 consecutive days when tumor volumes had reached 50-450 mm 3 , resulting in excision of the floxed Ptpn11 alleles. Mice lacking the R26 FSF-CAG-CreERT2 allele underwent the same procedure and served as controls. Dual recombination was confirmed by a double fluorescence/ bioluminescence reporter allele (R26
td-EG
), which, upon Flpo-mediated recombination, expresses E/GFP and firefly luciferase, and after Cre-mediated recombination, loses the E/GFP/firefly sequences and expresses tdTomato and Renilla luciferase.
For in vitro deletion of Ptpn11, a primary ex vivo PDAC cell line was established from a moribund Kras;Trp53 mice were initiated at an age of 28-35 days and were repeated weekly as described previously 48 . Sedation was performed via continuous inhalation of 2% isoflurane (Abbott) in O 2 using a veterinary anesthesia system (Vetland Medical). Body temperature was maintained and monitored, and eyes were protected by eye ointment. Image acquisition was achieved using a microscopy surface coil inside a 3.0 T clinical device (Philips) and an axial multislice T2-weighted turbo spin echo sequence (resolution: 0.3 × 0.3 × 0.7 mm ) were randomly assigned to trial arms and treated as specified below. Experiments were terminated once vehicle control tumors reached a critical size at the ethical end point (V = 2,000-4,000 mm 3 ). End-of-treatment tumor material was snap frozen in liquid nitrogen and stored at -80 °C for protein analysis.
Human pancreatic cancer cell line xenografts. Cells (numbers as indicated) were suspended in 100 µ l of a 1:1 mixture of DMEM and Matrigel (Corning) and injected subcutaneously into the flanks of NSG mice. Tumor volume was monitored as indicated above for the tissue xenografts. Therapy was initiated after tumors had reached a volume of 50-100 mm 3 . For drug dosing and schedule, see below.
Drugs and inhibitors. Trametinib, selumetinib, pictilisib, oxaliplatin and paclitaxel were purchased from Selleckchem, gemcitabine was provided by the Hospital Pharmacy of Klinikum Rechts der Isar (Technische Universität München), and GS493 and SHP099 were synthesized and kindly provided by M.N., Medicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany. PHPS1 (ref. 50 ) was obtained from Sigma-Aldrich. Drugs were dissolved in DMSO to yield 5-50 mM stock solutions and stored at − 80 °C.
In vivo therapy dosing. For in vivo application in Kras;Trp53
−/− and NSG mice, trametinib was diluted in 0.5% hydroxypropyl methylcellulose (Sigma-Aldrich) and 0.2% Tween 80 (Sigma-Aldrich) in water. GS493 was dissolved in Kolliphor EL (Sigma-Aldrich) and applied in an emulsion of 10% Kolliphor EL, 10% ethanol and water. Trametinib (1 mg per kg) was administered by oral gavage (Kras;Trp53 −/− mice: every other day; NSG mice: 5 days on, 2 days off), whereas GS493 was injected intraperitoneally (30 mg per kg, same schedule) 51 .
Histology and immunohistochemistry. Tissue specimens were either snap frozen in OCT (Sakura Finetek) or fixed in 4% buffered paraformaldehyde,
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NATuRE MEDIcINE dehydrated and embedded in paraffin wax. OCT (optimal cutting temperature compound) cryosections (10 µ m) were used for lineage tracing fluorescence microscopy after brief fixing in ethanol and nuclear staining with DAPI (Vector Laboratories). Formalin-fixed paraffin-embedded sections of 3 µ m were stained with H&E, Sirius Red or used for immunohistochemical studies.
Immunohistochemistry was performed on murine and human formalinfixed paraffin-embedded sections using avidin-biotin enhancement (Vector Laboratories). The following antibodies were used: SHP2 (3397; 1:200), pERK1/2 (4376; 1:100), pSTAT3 Y705 (9145; 1:100), pAKT (3787; 1:50), cleaved caspase 3 (9661; 1:200) from Cell Signaling, pSHP2 Y542 (ab62322; 1:500) and Ki67 (ab15580; 1:1,000) from Abcam, cyclin D1 (SP4; 1:100) from Thermo Scientific and Amylase (46657; 1:500) from Santa Cruz. Slides were developed with DAB (3,3'-diaminobenzidine, Vector Laboratories) and counterstained with hematoxylin. Image acquisition was achieved on a Zeiss AxioImager.A1 microscope. Quantitative analyses of tumor areas and immunohistochemistry staining were performed with Axiovision (Zeiss) and ImageJ softwares.
Cell culture and cell lines. Primary murine tumor cell lines were established from chopped pieces of explanted tumors without enzymatic digestion. All murine cell lines were routinely cultured in DMEM supplemented with 10% FBS and penicillin-streptomycin (100 U ml -1 , 100 µ g ml -1 ) (all Life Technologies , 100 µ g ml -1 ). All cells were kept at 37 °C in a humidified incubator with 5% CO 2 .
Plasmids, cloning and transfection. To generate CRISPR-Cas9 PTPN11 constructs, the pX458 vector was used to clone in guide RNAs (gRNAs) targeting the PTPN11 gene. The oligonucleotide sequences for both PTPN11 gRNAs are as follows: PTPN11 gRNA 1: forward: CACCGGAGGAACATGACATCGCGG, reverse: AAACCCGCGATGTCATGTTCCTCC; PTPN11 gRNA 2: forward: CCACGAACATGACATCGCGGAGGTG, reverse: AAACCACCTCCGCGATGTCATGTTC. Forward and reverse oligos for each gRNA were annealed and ligated into the Bbs1-digested pX458 vector. Target cells were subsequently transfected with the pX458-PTPN11-gRNA plasmids using polyethylenimine. Positively transfected cells expressing GFP were then FACS sorted as single cells in 96-well plates. Clones were allowed to grow out and analyzed for SHP2 status. SHP2-knockout clones were then named after the gRNA and clone name, for example, YAPC #1.1 refers to gRNA 1, clone 1.
For the SHP2 WT and SHP2 C459S reconstitution experiments, the pCMV-GFP plasmid was available in the Birchmeier laboratory, and pCMV-SHP2-WT (8381) and pCMV-SHP2-C459S (8382) plasmids were purchased from AddGene. SHP2-knockout clones were transfected with pCMV-GFP, pCMV-SHP2-WT or pCMV-SHP2-C459S using polyethylenimine. Subsequently, transfected cells were selected with G418 (800 µ g ml -1 G418 until non-transfected control cells were dead, then maintained in 200 µ g ml -1 G418), and clones that formed were picked and analyzed for SHP2 expression.
For the SHP2 E76A reconstitution experiment, pBp-SHP2-E76A was purchased from Addgene (8331); the control vector pBp-GFP was available in the Birchmeier laboratory. Using polyethylenimine, the plasmids were transfected in AmphoPack-293 cells (631505, Takara) to produce amphotrophic viral particles. The virus-containing supernatant was subsequently used to transduce PANC-1 PTPN11-knockout #2.6 cells in three consecutive rounds of infection. The viral supernatant was supplemented with 8 μ g ml -1 polybrene. Infected cells were then selected in 2 μ g ml -1 puromycin.
Phosphatase assay. To measure SHP2 phosphatase activity, sub-confluent cell lines (YAPC and PANC-1) were serum starved (0.1% FBS) for 18 h and then treated with selumetinib (or left untreated) in full-growth medium (10% FBS) for 24 h. Cells were then washed once with cold PBS and lysed on ice in cold PTP lysis buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM dithiothreitol, 2 mM EDTA, 0.5% Triton X-100 and 1:50 diluted protease inhibitor cocktail (Serva)). Cell lysate supernatants (2 mg each) were pre-cleared with Pierce Protein A/G Agarose (Life Technologies) for 1 h, transferred to a new tube and incubated with SHP2 antibody (3397, Cell Signaling) or a rabbit IgG control (Santa Cruz) at 4 °C on a rotator. Protein A/G Agarose beads (60 µ l each, 50% slurry) were added for an additional 2 h. Following a brief centrifugation, supernatants were collected for immunoblot analysis of immunoprecipitation efficiency. Immunoprecipitates were washed twice with PTP lysis buffer, twice with reaction buffer (25 mM HEPES, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol and 0.05% Triton X-100), followed by resuspension in 100 μ l reaction buffer containing 50 μ M DiFMUP (Biomol) and incubated at room temperature for 20 min. After a brief centrifugation, supernatants were transferred into a 96-well plate and the dephosphorylated DiFMUP (DIFMU) fluorescence signal was measured at 358 nm excitation and 455 nm emission on a FLUOstar OPTIMA plate reader. The remaining immune complexes were used for immunoblotting analysis of the SHP2 protein.
Proliferation assays. Cells were seeded in triplicate into 6-well plates and trypsinized, collected and counted using trypan blue and Countess Automated Cell Counter (Invitrogen) at indicated time points.
In vitro drug screening and colony formation assays. Cells were seeded into 6-, 12-or 24-well plates (20 × 10 3 , 5 × 10 3 or 1-4 × 10 3 cells per well, respectively) and allowed to adhere overnight in regular growth media. Cells were cultured in the absence or presence of drugs, as indicated, and refreshed every 2-3 days until the end of the experiment (on average, after 10-14 days). For each independent experiment, the different conditions were simultaneously fixed in 3.5% formaldehyde or 6% glutaraldehyde and subsequently stained with 0.1% crystal violet and digitalized on an image scanner. Relative growth was quantified by densitometry. All experiments were performed at least twice and representative results are shown.
Quantitative analysis of drug synergy. Drug synergy was calculated using CompuSyn software (version 1.0), which is based on the median-effect principle and the combination index-isobologram theorem 52 . CompuSyn software generates combination index values, where combination index < 0.75 indicates synergism, combination index = 0.75-1.25 indicates additive effects and combination index > 1.25 indicates antagonism. Following the instructions of the software, drug combinations at non-constant ratios were used to calculate the combination index in our study.
Patient-derived ex vivo PDAC organoid culture, treatment and read-out. Ex vivo organoids from resected human PDAC samples were generated and expanded as described previously 53 , with minor adaptations. To achieve conditions for highthroughput drug screening, single cells were isolated from established organoids by enzymatic digestion and gentle mechanical force. Cell-Matrigel suspensions were delivered into 96-well plates (1 × 10 3 cells per well) and single cells readily reformed organoids upon replating. After 24 h, titration treatments were initiated, and cell viability was measured 5 days after drug addition via CellTiter-Glo 3D Viability Assay (Promega) luminescence on a FLUOstar OPTIMA microplate reader (BMG Labtech). All donors provided written informed consent and experiments were approved by the local ethics committee of the Faculty of Medicine, Technische Universität München, Projects 1946/07 and 207/15.
Western blotting, RAS-RAF-RBD pulldown and phospho-arrays. Tissues were immediately snap frozen in liquid nitrogen at the time of organ harvest. Tissues or cells were lysed in Mg 2+ lysis buffer (125 mM HEPES, pH 7.5, 750 mM NaCl, 5% Igepal CA-630, 50 mM MgCl 2 , 5 mM EDTA and 10% glycerol; Millipore) or in RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate) supplemented with protease inhibitor (Serva or Roche) and phosphatase inhibitor cocktails (Serva or Sigma-Aldrich). Protein concentrations were determined by Bradford assay (Bio-Rad). For western blotting, proteins were separated by SDS-PAGE in Laemmli buffer, transferred to nitrocellulose or polyvinylidene difluoride (PVDF) membranes and detected with the following antibodies: ERK1/2 (9102 or sc-93/sc-154) and SHP2 (3397 or sc-280) were from Cell Signaling or Santa Cruz. AKT (9272), pAKT S473 (9271), cleaved caspase 3 (9661), insulin-like growth factor receptor-β (IGFR-β ; 3027), pIGFR-β Y1135/1136 (3024), MET (#8198), pMET Y1234/1235 (3126), RAS G12D -mutant specific (14429), STAT3 (9139), and pSTAT3 Y705 (9131) were purchased from Cell Signaling. Heat shock protein 90 (HSP90; sc-7947) and proliferating cell nuclear antigen (sc-56) were from Santa Cruz, and pSHP2 Y542 (ab51174) and KRAS (ab180772) were from Abcam. pan-RAS (05-516) was acquired from Millipore and β -actin-horseradish peroxidase (A3854) from Sigma-Aldrich. Signal detection was performed using horseradish peroxidase-conjugated secondary antibodies and an enhanced chemilumescent reagent (Amersham, GE Healthcare) followed by signal read-out in a Fusion SL-3 imaging system (Vilber) or by development on film. RAS-GTP levels were measured using the RAS Activation Assay Kit from Millipore (17-218) per manufacturer's instructions. Briefly, fresh pancreatic tissue or PDAC cell lines were lysed in ice-cold Mg 2+ lysis buffer and equal amounts of protein were incubated with RAF-1-RBD agarose beads for 45 min at 4 °C on a rotator. After three washing steps, beads were suspended in Laemmli-reducing sample buffer, subjected to SDS-PAGE and blotted on nitrocellulose membranes. Detection was performed with the indicated antibodies. The human Phospho-Kinase and Phospho-RTK Arrays were purchased from R&D Systems (ARY003B and ARY001B, respectively) and nature research | life sciences reporting summary 
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
GraphPad PRISM 7.0c
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Unique materials used are readily available from the authors (SHP2 inhibitor: GS493).
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
For immunohistochemistry: SHP2 (#3397; 1:200), pERK1/2 (#4376; 1:100), pSTAT3 Y705 (#9145; 1:100), pAKT (#3787; 1:50), Cleaved Caspase 3 (#9661; 1:200) from Cell Signaling, pSHP2 Y542 (ab62322; 1:500) and Ki67 (ab15580; 1:1000) from Abcam, Cyclin D1 (SP4; 1:100) from Thermo Scientific, and Amylase (#46657; 1:500) from Santa Cruz. All antibodies were validated for IHC application by the manufacturer as stated in the respective datasheets, except for SHP2 #3397 from Cell Signaling, which was established and validated using murine conditional SHP2-knockout pancreata as negative controls (cf. Supplementary Fig. 2a ).
For immunoblotting: ERK1/2 (#9102 or sc-93/sc-154) and SHP2 (#3397 or sc-280) were from Cell Signaling or Santa Cruz. AKT (#9272), pAKT S473 (#9271), Cleaved Caspase 3 (#9661), IGFR (#3027), pIGFR Y1135/1136 (#3024), MET (#8198), pMET Y1234/1235 (#3126), RASG12D mutant specific (#14429), STAT3 (#9139), and pSTAT3 Y705 (#9131) were purchased from Cell Signaling. HSP90 (sc-7947) and PCNA (sc-56) were from Santa Cruz, pSHP2 Y542 (ab51174 and ab62322) was from Abcam. pan-RAS (05-516) was acquired from Millipore and β-actin-HRP (A3854) from Sigma-Aldrich. All antibodies are validated by the manufacturer for the relevant applications and species analyzed.
